Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125

Phase 1 Completed 9 enrolled Aquinox Pharmaceuticals (Canada) Inc. Quotient Clinical · collab

Non-randomizedSequentialOpen-labelBasic science

Summary

This study is conducted to evaluate the absolute bioavailability, metabolism and elimination pathways of AQX-1125 in healthy male and female subjects.

Timeline

Start: 2016-11-22
Primary completion: 2017-01-04
Completion: 2017-01-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ROSIPTOR	Small molecule	—	Oral

Indications

No indication recorded.